Ocumetics Technology Corp. announced positive three-month postoperative results from Group 1 patients in its first-in-human clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the company's core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program. According to Dean Burns, President and CEO of Ocumetics, these results demonstrate safe implantation, reliable delivery, and strong visual outcomes. Following a detailed review of the data with Dr. Raphael Vasquez, the primary surgeon, management remains fully confident in the accommodating intraocular lens technology.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics Lens. Dr. Rafael Vázquez MD, principal investigator of the Ocumetics first-in-human trial, noted that all patient outcomes have met safety expectations, and patients have experienced truly life-changing events. From being classified legally blind, patients can now read, enjoy everyday life activities, and drive, with remarkable impact on their independence and sense of freedom.
The results from Group 1 can be summarized as meeting expectations for safety profile, exceeding expectations for visual acuity outcomes, and meeting expectations for lens delivery system. Based on this success, Ocumetics has initiated planning for Group 2 surgeries. The company continues to apply its rapid "win-learn" R&D approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from Group 1, the company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2.
Manufacturing and testing of optimized lens designs are currently underway, with Group 2 surgeries expected to be scheduled following completion of final lens testing and validation. According to Burns, this milestone materially strengthens the clinical foundation and positions Ocumetics to build momentum as the company advances into Group 2. The company remains excited to continue executing on its clinical and development roadmap. For more information about the study results, the company has scheduled a webinar available at https://www.ocumetics.com/webinar.
